Molecule Details
InChIKeyYSXKPIUOCJLQIE-UHFFFAOYSA-N
Compound NameBiperiden
Canonical SMILESOC(CCN1CCCCC1)(c1ccccc1)C1CC2C=CC1C2
Clinical Status Data-mined Candidate
Targets (Human+Pathogen)5
Pfam Stratification Homologous
Avg pChEMBL8.08
SourceBindingDB;ChEMBL
2D Structure
2D structure
Activity Profile
DrugBank Annotations
DrugBank ID DB00810
Drug NameBiperiden
CAS Number514-65-8
Groups approved investigational withdrawn
ATC Codes N04AA02
DescriptionA muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reser...

Categories: Agents producing tachycardia Anti-Dyskinesia Agents Anti-Parkinson Drugs Anticholinergic Agents Autonomic Agents Aza Compounds Azabicyclo Compounds Bridged-Ring Compounds Central Nervous System Agents Cholinergic Agents Cytochrome P-450 CYP2D6 Inhibitors Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) Cytochrome P-450 Enzyme Inhibitors Muscarinic Antagonists Nervous System Neurotransmitter Agents Nicotinic Antagonists Parasympatholytics Peripheral Nervous System Agents Piperidines Tertiary Amines
Cross-references: BindingDB: 50240680 ChEBI: 3112 CHEMBL1101 ChemSpider: 2289 Drugs Product Database (DPD): 6471 C07941 D00779 PharmGKB: PA448626 PubChem:2381 PubChem:46508325 RxCUI: 1589 Therapeutic Targets Database: DAP001125 Wikipedia: Biperiden
Target Activities (5)
Target Gene Organism Category Pfam pChEMBL Type Source
P11229 CHRM1 Homo sapiens Human PF00001 8.6 Ki ChEMBL;BindingDB
P20309 CHRM3 Homo sapiens Human PF00001 8.2 Ki ChEMBL;BindingDB
P08912 CHRM5 Homo sapiens Human PF00001 8.2 Ki BindingDB
P08172 CHRM2 Homo sapiens Human PF00001 7.9 Ki ChEMBL;BindingDB
P08173 CHRM4 Homo sapiens Human PF00001 7.5 Ki ChEMBL;BindingDB
DrugBank Target Actions (2)
Target Gene Target Name Action Type
P10635 CYP2D6 Cytochrome P450 2D6 inhibitor enzymes
P11229 CHRM1 Muscarinic acetylcholine receptor M1 antagonist targets